Neurohumoral Prediction of Benefit From Carvedilol in Ischemic Left Ventricular Dysfunction
| Autor: | Hamid Ikram, Timothy G. Yandle, Arthur Mark Richards, Stephen MacMahon, Chris Frampton, Norman Sharpe, E. A. Espiner, Robert N. Doughty, Michael Gary Nicholls |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Ejection fraction Heart disease business.industry medicine.drug_class medicine.disease Placebo Brain natriuretic peptide Atrial natriuretic peptide Physiology (medical) Internal medicine Heart failure medicine Cardiology Natriuretic peptide Cardiology and Cardiovascular Medicine business Carvedilol medicine.drug |
| Zdroj: | Circulation. 99:786-792 |
| ISSN: | 1524-4539 0009-7322 |
| DOI: | 10.1161/01.cir.99.6.786 |
| Popis: | Background —Plasma neurohormones were analyzed for prediction of adverse outcomes and response to treatment in 415 patients with ischemic left ventricular dysfunction randomly assigned to receive carvedilol or placebo. Methods and Results —Atrial natriuretic peptide, brain natriuretic peptide (BNP), or norepinephrine (NE) levels above the group median were associated with increased mortality rates and heart failure. On multivariate analysis, both BNP and NE interacted with treatment to predict death or heart failure independent of age, New York Heart Association class, and left ventricular ejection fraction. For placebo, supramedian levels of BNP were associated with 3-fold the mortality rate of inframedian levels (20/104; 19% vs 6/99; 6%; P P P 90% ( P Conclusions —Carvedilol reduced mortality rates and heart failure in those with higher pretreatment BNP levels but lesser activation of plasma NE. Neurohumoral profiling may guide introduction of β-blockade in heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|